Adjuvant osimertinib in EGFR lung cancer: ADAURA

A 58-year-old teacher who never smoked has a CT scan because of a cough that would not go away. The scan shows a 4-centimeter nodule in the right lower lobe. The biopsy confirms adenocarcinoma, and staging shows no disease outside the chest. She undergoes surgery and the lobectomy removes the tumor completely, with clear margins. Two hilar lymph nodes come back positive, and the final report says stage II. The team meets to decide what comes after surgery, and someone asks whether EGFR testing was done. Nobody knows for sure. The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. The topic is adjuvant osimertinib in non-small cell lung cancer with an EGFR mutation, based on the ADAURA trial, and the question Dr. Alexei proposed for the series: which operated patients may miss a therapeutic opportunity if EGFR is not tested? Along with it comes another question from the same list: which biomarkers need to be available before the perioperative decision, and how can decisions with incomplete results be avoided? The text does not replace your country's guideline or your institution's protocol. If you play the case of the day on NEXO, you will recognize the challenge: the clue that changes everything is sometimes a test nobody ordered.

Key points

• ADAURA compared osimertinib with placebo after complete resection of tumors with exon 19 deletion or EGFR L858R mutation, in stages IB to IIIA.
• Osimertinib greatly reduced recurrence and, in the final analysis, also reduced the risk of death.
• The dose studied was 80 mg orally once a day for up to 3 years.
• The benefit depends on knowing the EGFR result. Without the test, the operated patient misses the indication.
• Adjuvant chemotherapy remains a separate decision, guided by stage and risk.
• Central nervous system recurrences were less frequent with osimertinib, but some appeared after treatment ended.

Why this is a reasoning scenario

For a long time, treatment after lung cancer surgery followed a simple rule. Those with a larger tumor or a positive lymph node received platinum chemotherapy, and those with a small tumor were followed. The gain from chemotherapy existed, but it was modest. An old meta-analysis, cited in the review by Zhang and Ou, showed an absolute survival benefit of about 5 points at 5 years with cisplatin-based chemotherapy (Zhang and Ou, 2022). Most patients who recurred kept recurring.

ADAURA changed this conversation for a subgroup defined by tumor biology. The difference does not appear on physical examination, on the CT scan or in the routine report of the specimen. It only appears if someone orders the molecular test. That is why the topic suits clinical reasoning so well: the most common mistake is not choosing the wrong drug, but failing to ask the question that leads to the right drug.

The reasoning here has three layers. The first is recognizing the patient who may have the mutation. The second is making sure the result is on the table before any decision about systemic treatment. The third is interpreting the benefit honestly, without promising a cure and without minimizing toxicity. All three require teamwork, a subject the series has already covered in the post about the multidisciplinary team in lung cancer.

What makes this mistake easy to make

The operated patient is usually doing well. The surgery went without complications, the report says clear margins, and the conversation can turn into a celebration. At that moment, it seems the work is done. The question about EGFR depends on someone remembering that, after surgery, microscopic disease may still be in the body. The post about the diagnostic pause describes exactly this moment of stopping before closing the case.

Who is a candidate: the mutation as a clue

ADAURA included adults with completely resected non-squamous non-small cell lung cancer, pathological stage IB (T2a tumors larger than 3 and up to 5 centimeters), II or IIIA by the seventh edition of the AJCC/UICC system, with exon 19 deletion or L858R EGFR mutation confirmed at a central laboratory (Herbst et al., 2023). These two alterations are the most common sensitizing mutations and the ones that respond best to tyrosine kinase inhibitors.

The classic epidemiological clue, that the EGFR mutation appears more often in women, non-smokers and people of Asian ancestry, helps to remember the test, but it does not serve to decide whom to test. Smokers can also have the mutation, and the current guideline calls for testing in every operated adenocarcinoma that could receive adjuvant treatment. The review by Zarinshenas et al. on early-stage disease recalls that treatment today requires a multidisciplinary approach and that molecular testing is part of the diagnosis, not of a later step (Zarinshenas et al., 2023).

Who is left out

The study did not include the rare EGFR mutations, such as exon 20 or G719X, nor patients with incomplete resection. It also did not include stage IA or pure squamous cell carcinoma. In practice, this means the indication applies to the group studied, and any extrapolation must be discussed as such. For tumors with ALK rearrangement, the evidence is different, that of the ALINA study, which the series explains in the post on adjuvant alectinib.

Biomarkers before the perioperative decision

Dr. Alexei's question about biomarkers has gained weight in recent years because perioperative treatment has split into mutually exclusive paths. A patient with resectable disease may receive immunotherapy before surgery, immunotherapy before and after, targeted therapy afterwards, or chemotherapy alone. The choice depends on EGFR, ALK and PD-L1. Starting induction immunotherapy without knowing the EGFR status can lead a patient with the mutation to a treatment that brings little benefit for that profile and that can complicate the use of the inhibitor later. The series discusses this point in the post on perioperative pembrolizumab.

In practice, the result does not always arrive in time. In an Italian study with 1,817 patients from referral centers and smaller centers, EGFR was available in 78 out of every 100 samples, and fewer than half of the patients had all 5 biomarkers of the panel (Tinè et al., 2024). The same study showed that cytology had more samples without a result than biopsy and the surgical specimen (Tinè et al., 2024).

A database of community health systems in the United States, with 8,501 patients in stages I to III, showed that EGFR testing rose from 51 to 82 out of every 100 patients between 2020 and 2023 (Hu et al., 2025). The same study found higher testing rates in counties without a shortage of primary care physicians, and a median time of 41 days between diagnosis and first treatment (Hu et al., 2025). Access to testing, therefore, still depends on where the patient is treated.

How to avoid deciding with an incomplete result

• Order the molecular panel at diagnosis, reflexively, for every non-squamous carcinoma that could be operated on.
• Plan the biopsy to obtain enough tissue for histology, immunohistochemistry and molecular testing.
• If the initial sample fails, test the surgical specimen before defining adjuvant treatment.
• Record in the medical chart which results have already arrived and which are pending before the team meeting.
• Do not start induction immunotherapy while EGFR and ALK are pending.

What ADAURA tested

ADAURA was a phase III, double-blind study that randomized 682 patients in a 1 to 1 ratio between osimertinib and placebo after complete resection (Herbst et al., 2023). Adjuvant chemotherapy was permitted before randomization, at the discretion of the physician and the patient. Randomization was stratified by mutation type, stage and race.

Osimertinib was given at a dose of 80 mg orally once a day until recurrence, a criterion for discontinuation or the 3-year limit (Herbst et al., 2023). The primary outcome was disease-free survival in the stage II to IIIA group. Secondary outcomes included disease-free survival in the entire stage IB to IIIA population, overall survival and safety. Quality of life was measured with the SF-36 questionnaire (Majem et al., 2022).

Why placebo, and not chemotherapy

The placebo control answered the question "does adding osimertinib after the standard improve the result?". It did not answer whether osimertinib replaces chemotherapy. This difference matters for interpretation and comes back later, in the section on chemotherapy. Earlier Asian studies with gefitinib and erlotinib had compared the inhibitor with chemotherapy and shown a gain in disease-free survival, but without a clear gain in overall survival in some of them (Zhang and Ou, 2022).

What ADAURA showed

In the updated analysis, with a data cutoff in April 2022, the hazard ratio for disease-free survival in stage II to IIIA was 0.23, and the 4-year rate was 70 in every 100 patients with osimertinib versus 29 with placebo (Herbst et al., 2023). In the entire stage IB to IIIA population, the hazard ratio was 0.27, with 4-year rates of 73 and 38 in every 100 (Herbst et al., 2023).

The overall survival analysis came later. The authors' official summary reports that, both in the stage II to IIIA group and in the general population, osimertinib reduced the risk of death by about half compared with placebo (Tsuboi et al., 2024). It was this result that brought Dr. Alexei's question to the center: a patient who has had surgery and does not undergo EGFR testing misses an intervention that has shown increased survival.

Central nervous system and quality of life

The hazard ratio for disease-free survival in the central nervous system, in stage II to IIIA, was 0.24 (Herbst et al., 2023). But the same article shows that 15 of the 18 central nervous system recurrences in the osimertinib group appeared after the end or discontinuation of treatment (Herbst et al., 2023). Quality of life remained stable throughout treatment, with no clinically relevant difference compared with placebo (Majem et al., 2022).

The Chinese subanalysis, with 159 patients, showed results similar to those of the global population, with a hazard ratio of 0.23 for disease-free survival in stage II to IIIA (Wang et al., 2024).

Outcome	Osimertinib	Placebo	Source
4-year disease-free survival, stage II to IIIA	70 in every 100	29 in every 100	Herbst 2023
4-year disease-free survival, stage IB to IIIA	73 in every 100	38 in every 100	Herbst 2023
Hazard ratio for central nervous system recurrence, stage II to IIIA	0.24		Herbst 2023
Risk of death	reduced by about half		Tsuboi 2024
Completed the planned 3 years	66 in every 100	41 in every 100	Herbst 2023
Interstitial lung disease	11 patients, grades 1 and 2	none	Herbst 2023

How to use adjuvant osimertinib

The dose studied is 80 mg orally once a day for up to 3 years (Herbst et al., 2023). In the study, 66 in every 100 patients in the osimertinib group completed the 3 years, versus 41 in the placebo group, partly because recurrence ended treatment earlier in the placebo group (Herbst et al., 2023).

Toxicity the team needs to know about

The most common adverse events were diarrhea, paronychia and dry skin (Herbst et al., 2023). Interstitial lung disease appeared in 11 patients, all grade 1 or 2 and none fatal, and QT interval prolongation on the electrocardiogram was recorded in 30 patients (Herbst et al., 2023). Outside the study, there are reports of severe interstitial lung disease after adjuvant osimertinib, which reinforces advising the patient to report new shortness of breath (Mitsuya et al., 2024).

• Electrocardiogram before starting and during treatment, especially with other medicines that prolong QT.
• Watch for cough, shortness of breath and fever, which may be signs of pneumonitis.
• Care for the skin and nails from the start, with moisturizing and guidance about paronychia.
• Review of drug interactions at the pharmacy, since treatment lasts years.
• Regular appointments to support adherence, which is a challenge in people who feel well.

The value of disease-free survival

Before overall survival data came out, there was debate about the value of disease-free survival as an outcome. An international panel using Delphi methodology reached 32 consensus statements on the value of disease-free survival and adjuvant osimertinib (Hardenberg et al., 2022). For teaching, the lesson is useful: an intermediate outcome can be relevant to the patient, since delaying recurrence has value in itself, but it is the overall survival gain that settles the discussion.

Chemotherapy, recurrence and molecular residual disease

Osimertinib did not eliminate the question about adjuvant chemotherapy. In ADAURA, the decision to give chemotherapy before osimertinib was left to the physician, and the benefit of osimertinib appeared with or without prior chemotherapy (Herbst et al., 2023). Zhang and Ou argued that platinum-based chemotherapy could be omitted when osimertinib is used for 3 years, with a possible exception for tumors with RB alterations (Zhang and Ou, 2022). This is a position held by the authors, not the result of a comparative study.

In stage IB, the doubt is even greater. A Korean study of 178 patients with stage IB adenocarcinoma with an EGFR mutation found no significant difference in recurrence-free survival between those who received and those who did not receive adjuvant chemotherapy, and the authors conclude that the efficacy of chemotherapy in this group remains uncertain (Park et al., 2025). The decision, therefore, should be shared and documented.

Molecular residual disease

An exploratory analysis of 220 ADAURA patients studied circulating tumor DNA in plasma to detect molecular residual disease (Herbst et al., 2025). Detection preceded clinical recurrence by a median of 4.7 months, and most patients in the osimertinib group with detectable disease at randomization had the signal cleared during treatment (Herbst et al., 2025). The study is exploratory. It does not justify stopping treatment based on the blood test, but it helps explain why some recurrences appear after 3 years.

When the disease comes back

An international consensus on recurrence during or after adjuvant osimertinib recommends a new tissue biopsy for histological and molecular analysis whenever possible, with a liquid biopsy when tissue cannot be obtained (Mirza et al., 2023). The same panel notes that there is still no clinically validated molecular residual disease test (Mirza et al., 2023). The reasoning, once again, is about clues: where the disease came back, when it came back in relation to treatment and what biology it has now.

And in unresectable stage III disease

The LAURA study brought osimertinib into consolidation after chemoradiotherapy in unresectable stage III. A review on the topic reports a strong reduction in the risk of distant metastasis or death with osimertinib in this setting (Luo et al., 2025). This is another patient and another question, but it reinforces the same lesson: EGFR must be known in all stages.

Common reasoning errors

• Assuming that the EGFR mutation only appears in people who never smoked and failing to test smokers.
• Closing the adjuvant plan based only on staging, without the molecular result.
• Starting induction immunotherapy without knowing EGFR and ALK status.
• Treating disease-free survival as a synonym for cure.
• Forgetting the electrocardiogram and guidance on respiratory symptoms.

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by looking for the ICD-10 code. Adjuvant osimertinib is a good exercise because the decisive clue is a test that must be remembered, not a finding that appears on its own. The post about differential diagnosis shows how to organize the clues, and the post about clinical decision-making helps you think about when to order each test.

Three exercises with cases

Change the mutation. Say what changes if the report showed an exon 20 insertion instead of an exon 19 deletion.

Change the stage. Say how you would talk about chemotherapy if the tumor were stage IB and 3.5 centimeters.

Change the timing. Say what you would do if the patient had a brain metastasis one year after finishing the 3 years of osimertinib.

The post about diagnostic uncertainty helps train the conversation about benefit and doubt. The limits of use of the game are described on the NEXO Economy page. If you research the teaching of clinical reasoning, the page for Researchers explains how to get in touch. Professionals who write or review cases find information in Curator and in Creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Does adjuvant osimertinib increase survival?

Yes. In the final ADAURA analysis, the risk of death fell by about half compared with placebo (Tsuboi et al., 2024).

What is the dose and for how long?

In the study, 80 mg orally once a day, for up to 3 years (Herbst et al., 2023). Check the package insert in your country before prescribing.

Who should have the EGFR test?

Every non-squamous carcinoma that has been operated on and could receive adjuvant treatment, regardless of smoking history. The test should be ready before the systemic decision.

Does osimertinib replace chemotherapy?

ADAURA compared osimertinib with placebo and allowed prior chemotherapy. It did not answer whether one replaces the other, and the decision follows the stage and the risk (Zhang and Ou, 2022).

Does the blood DNA test define when to stop?

Not yet. The molecular residual disease analysis of ADAURA was exploratory, and there is no validated test for this decision (Mirza et al., 2023).

Final checklist

• I ordered EGFR, ALK and PD-L1 at diagnosis or on the surgical specimen.
• I confirmed complete resection and the pathological stage.
• I checked whether the mutation is an exon 19 deletion or L858R.
• I discussed adjuvant chemotherapy according to the stage.
• I explained the benefit in recurrence and in survival, without promising a cure.
• I did an electrocardiogram and reviewed interactions.
• I gave guidance on skin, nails, diarrhea and respiratory symptoms.
• I planned imaging follow-up, including after the end of the 3 years.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Hardenberg MC, Patel B, Matthews C, et al. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report. ESMO Open. 2022. PMID 36108559.
2. Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025. PMID 40097663.
3. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023. PMID 36720083.
4. Hu X, Kao YH, Arunachalam A, et al. Trends in initial primary treatment approach and biomarker testing across social determinants of health in early-stage non-small cell lung cancer. Future Oncol. 2025. PMID 41257359.
5. Luo FX, Arter Z, Ou SI, Nagasaka M. LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154). Lung Cancer (Auckl). 2025. PMID 40313586.
6. Majem M, Goldman JW, John T, et al. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clin Cancer Res. 2022. PMID 35012927.
7. Mirza M, Shrivastava A, Matthews C, et al. Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report. Front Oncol. 2023. PMID 38322280.
8. Mitsuya S, Arai M, Kanaoka K, et al. Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report. JTO Clin Res Rep. 2024. PMID 38322711.
9. Park SH, Park JH, Kim TH, et al. Adjuvant chemotherapy before osimertinib in EGFR-mutated stage IB lung adenocarcinoma: a clinical dilemma. Transl Lung Cancer Res. 2025. PMID 41133014.
10. Tinè M, Pezzuto F, Orlandi M, et al. Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers. Transl Lung Cancer Res. 2024. PMID 39118890.
11. Tsuboi M, Herbst RS, John T, et al. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. Target Oncol. 2024. PMID 38466534.
12. Wang J, Wu YL, Lu S, et al. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis. JTO Clin Res Rep. 2024. PMID 38371194.
13. Zarinshenas R, Amini A, Mambetsariev I, et al. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers (Basel). 2023. PMID 36900386.
14. Zhang SS, Ou SI. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. Lung Cancer (Auckl). 2022. PMID 35506019.